“…The ET A receptor mediates ET-1’s effects in prostate, ovarian, breast, renal, bladder, cervical cancer and bone malignancies, 8,40, 88, 100, 182, 202, 223 while both ET A and ET B receptor subtypes are presumably responsible for ET-1’s actions in colon cancer and Kaposi’s sarcoma. 180, 201 Endothelins also modulate the trafficking, differentiation and activation of tumor-infiltrating immune cells. 10, 85…”